Key Takeaways
- On March 5, the FDA issued a warning letter to Novo Nordisk regarding inadequate reporting of adverse events associated with semaglutide, found in Ozempic and Wegovy.
- The letter highlighted three fatalities, including a suicide that Novo allegedly failed to properly investigate or report in a timely manner.
- Novo Nordisk has a 14-day deadline to outline corrective measures to the FDA.
- Despite the warning, the pharmaceutical giant maintains that production schedules and financial projections remain unaffected.
- Shares of NVO have declined 27% year to date, currently hovering near $38.32.
It’s been a challenging year for Novo Nordisk, and recent regulatory scrutiny is adding to the pressure.
The Food and Drug Administration delivered a warning letter to the Copenhagen-based pharmaceutical company dated March 5, pointing to “serious violations” in its adverse event reporting practices for semaglutide, the key compound in both Ozempic and Wegovy.
These infractions came to light during a regulatory inspection at the company’s New Jersey location conducted in the previous year.
The FDA’s letter specifically mentioned three fatalities—two deaths and one suicide—with particular emphasis on Novo’s alleged failure to properly investigate and report the suicide case according to regulatory timelines.
It’s important to note that the FDA has not established a causal relationship between these medications and the reported deaths. The agency’s primary concern centers on procedural compliance in reporting adverse events, not whether the drugs directly caused harm.
“FDA relies on the complete, accurate, and timely submission of ADEs to monitor a product’s safety profile,” the regulatory body stated, using the abbreviation for adverse drug events.
Novo Nordisk now faces a two-week deadline to inform the FDA about its remediation plan to ensure compliance moving forward.
In a public statement, the pharmaceutical company indicated it has been actively working to resolve the FDA’s concerns. The firm confirmed submitting an initial response along with seven subsequent updates to the agency.
The company stated that the referenced cases “have been evaluated” and are now “processed and reported appropriately.” However, Novo did not dispute the initial reporting failures.
Mounting Regulatory Scrutiny
This warning letter represents just one piece of a broader regulatory puzzle facing Novo Nordisk. In December, the company received another FDA warning letter directed at its Bloomington, Indiana manufacturing site concerning Good Manufacturing Practice violations.
More recently, the FDA sent two additional letters in late February criticizing promotional materials for Ozempic and Wegovy, alleging “false or misleading claims” regarding the drugs’ effectiveness and safety profiles. A February 26 letter specifically took issue with Novo’s positioning of Ozempic as superior to competitor medications.
In its press statement, Novo acknowledged the regulatory environment, stating matter-of-factly: “We work in a highly regulated space.”
The company maintains that this latest warning letter will not disrupt manufacturing operations or alter the financial outlook previously communicated to shareholders.
Shares Sink 27% in 2026
NVO shares have experienced significant downward pressure this year. Trading at approximately $38.32, the stock has shed 27% of its value year to date, marking a substantial retreat from previous peaks.
The decline stems from multiple factors—intensifying regulatory oversight and mounting competition from Eli Lilly’s Mounjaro, a competing GLP-1 medication, have both contributed to negative investor sentiment.
Political factors have compounded the challenges. Health Secretary RFK Jr. has openly criticized Ozempic’s pricing structure, and previously opposed a Biden administration initiative that would have extended Medicare coverage for GLP-1 drugs to approximately 7 million beneficiaries.
As of Tuesday afternoon, the stock was changing hands at $38.32.
